Kymera Therapeutics (NASDAQ:KYMR) is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company’s pipeline emphasizes immunology and oncology. Its lead program, a degrader targeting interleukin‐1 receptor–associated kinase 4 (IRAK4), is being evaluated for inflammatory and autoimmune diseases. In parallel, Kymera is advancing degraders against transcription factors and other intracellular targets implicated in hematologic malignancies. Preclinical efforts also include collaborations with global pharmaceutical partners to expand the application of its protein‐degradation technology to additional disease routes.
Kymera operates research and development facilities in Massachusetts and maintains collaborations with academic institutions and biotech partners in North America and Europe. The company’s multi‐disciplinary team brings together expertise in structural biology, chemistry, pharmacology and clinical development. Since becoming a publicly traded company on the Nasdaq exchange under the ticker symbol KYMR, Kymera has continued to build its leadership bench to support late‐stage trials, regulatory interactions and future commercialization efforts.
Rick Wagner serves as President and Chief Executive Officer, leading Kymera through its transition from a discovery‐focused entity to a clinical‐stage organization. Under his guidance, the company has expanded its internal capabilities and entered strategic research partnerships to accelerate the development of protein degraders. As Kymera progresses key programs into later‐stage clinical studies, it aims to validate targeted protein degradation as a new therapeutic modality that can address diseases with limited treatment options.
